Platelet-Specific Proteins in Myeloproliferative Disorders
نویسندگان
چکیده
منابع مشابه
Increased platelet-fibrinogen affinity in patients with myeloproliferative disorders.
Patients with myeloproliferative disorders (MPD) are known to have some abnormalities of platelet glycoproteins (Gp). Quantitative changes of the Gp Ib, IIb-IIIa, and/or their glucidic content have been reported. Since the Gp IIb-IIIa complex plays a major role in fibrinogen binding by activated platelets, we measured the platelet fibrinogen affinity in nine patients with polycythemia vera (PV)...
متن کاملPlatelet function and thromboxane synthesis in myeloproliferative disorders.
We have read with interest the paper of Landolfi et al,’ “Increased Thromboxane Biosynthesis in Patients With Polycythemia Vera: Evidence for Aspirin-Suppressible Platelet Activation In Vivo.” In a recent publication’ on 1 1 patients with chronic myeloproliferative disorders (CMPD), 7 with essential thrombocytosis and 4 with polycytnemia vera, we have reached a similar conclusion (with respect ...
متن کاملPlatelet resistance to prostaglandin D2 in patients with myeloproliferative disorders.
We investigated the effect of prostaglandin 03 (PGD2) on platelet adenylate cyclase activity in 23 patients with myeloproliferative disorders, including eight patients with polycythemia vera, seven with myeloid metaplasia, four with chronic myelogenous leukemia. and four with essential thrombocythemia. In 20 of these patients there was less activation of platelet adenylate cyclase at all concen...
متن کاملMutant Cbl proteins as oncogenic drivers in myeloproliferative disorders
Casitas B-lineage lymphoma (Cbl) family proteins are evolutionarily-conserved attenuators of protein tyrosine kinase (PTK) signaling. Biochemical analyses over the past two decades have firmly established that the negative regulatory functions of Cbl proteins are mediated through their ability to facilitate ubiquitination and thus promote degradation of PTKs. As aberrant activation of PTKs is f...
متن کاملPlatelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders.
Our enzyme-linked immunosorbent assay (ELISA) for measuring human platelet-derived growth factor (PDGF) detects nanogram quantities (ranging from 0.007 to 16 ng/100 microL) in purified PDGF standards. This assay is sensitive enough for studying plasma and urine. The range in normal volunteers was 0.6 to 2.3 micrograms/L for platelet-poor plasma and 1.4 to 3.3 micrograms/L for urine. We determin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Acta Haematologica
سال: 1992
ISSN: 0001-5792,1421-9662
DOI: 10.1159/000204772